S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Zymeworks Stock Forecast, Price & News

-1.75 (-8.65%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
482,953 shs
Average Volume
514,270 shs
Market Capitalization
$860.78 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

Zymeworks logo

About Zymeworks

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.


Zymeworks (NYSE:ZYME) Sets New 1-Year Low at $18.09
November 23, 2021 |  americanbankingnews.com
Zymeworks (NYSE:ZYME) Trading 5.2% Higher
November 22, 2021 |  americanbankingnews.com
Zymeworks Inc. (NYSE:ZYME) Short Interest Down 22.6% in October
November 20, 2021 |  americanbankingnews.com
Zymeworks (NYSE:ZYME) Hits New 1-Year Low at $18.79
November 16, 2021 |  americanbankingnews.com
Zymeworks (NYSE:ZYME) Rating Reiterated by SVB Leerink
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$38.95 million
Book Value
$5.99 per share


Net Income
$-180.55 million
Net Margins
Pretax Margin




Free Float
Market Cap
$860.78 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.17 out of 5 stars

Medical Sector

424th out of 1,388 stocks

Pharmaceutical Preparations Industry

194th out of 668 stocks

Analyst Opinion: 4.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Zymeworks (NYSE:ZYME) Frequently Asked Questions

Is Zymeworks a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 3 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zymeworks stock.
View analyst ratings for Zymeworks
or view top-rated stocks.

How has Zymeworks' stock price been impacted by COVID-19?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZYME stock has decreased by 42.7% and is now trading at $18.49.
View which stocks have been most impacted by COVID-19

Are investors shorting Zymeworks?

Zymeworks saw a drop in short interest in the month of October. As of October 29th, there was short interest totaling 3,520,000 shares, a drop of 22.6% from the October 14th total of 4,550,000 shares. Based on an average daily volume of 504,400 shares, the short-interest ratio is currently 7.0 days. Currently, 7.7% of the shares of the stock are short sold.
View Zymeworks' Short Interest

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Zymeworks

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) released its earnings results on Wednesday, November, 3rd. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.17) by $0.08. Zymeworks had a negative trailing twelve-month return on equity of 60.71% and a negative net margin of 936.34%.
View Zymeworks' earnings history

What price target have analysts set for ZYME?

8 equities research analysts have issued 1 year target prices for Zymeworks' shares. Their forecasts range from $32.00 to $74.00. On average, they expect Zymeworks' stock price to reach $49.38 in the next twelve months. This suggests a possible upside of 167.0% from the stock's current price.
View analysts' price targets for Zymeworks
or view top-rated stocks among Wall Street analysts.

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Ali Tehrani, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Neil Klompas, Chief Financial Officer & EVP-Business Operations
  • Anthony J. Polverino, Chief Scientific Officer & EVP-Early Development
  • Neil Josephson, Chief Medical Officer
  • Mark Hollywood, Senior VP-Technical & Manufacturing Operations

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks CEO Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among Zymeworks' employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (7.90%), Morgan Stanley (4.93%), BlackRock Inc. (1.67%), Camber Capital Management LP (1.61%), Wellington Management Group LLP (1.29%) and Thrivent Financial for Lutherans (0.79%). Company insiders that own Zymeworks stock include Ali Tehrani, Diana Hausman, James Priour, Kathryn O'driscoll, Neil A Klompas and Troy Cox.
View institutional ownership trends for Zymeworks

Which major investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Two Sigma Advisers LP, Morgan Stanley, CI Investments Inc., HAP Trading LLC, Citadel Advisors LLC, and WINTON GROUP Ltd. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, James Priour, Kathryn O'driscoll, and Neil A Klompas.
View insider buying and selling activity for Zymeworks
or view top insider-selling stocks.

Which major investors are buying Zymeworks stock?

ZYME stock was bought by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Wellington Management Group LLP, Goldman Sachs Group Inc., Millennium Management LLC, Picton Mahoney Asset Management, Platinum Investment Management Ltd., GSA Capital Partners LLP, and Integral Health Asset Management LLC. Company insiders that have bought Zymeworks stock in the last two years include Ali Tehrani, and Troy Cox.
View insider buying and selling activity for Zymeworks
or or view top insider-buying stocks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $18.49.

How much money does Zymeworks make?

Zymeworks has a market capitalization of $860.78 million and generates $38.95 million in revenue each year. The company earns $-180.55 million in net income (profit) each year or ($4.17) on an earnings per share basis.

How many employees does Zymeworks have?

Zymeworks employs 354 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

Where are Zymeworks' headquarters?

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at (604) 678-1388, via email at [email protected], or via fax at 604-737-7077.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.